戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  and patient education regarding dietary and medication compliance.
2 ave high OOP expenses, associated with lower medication compliance.
3 pect to the role of treatment attendance and medication compliance.
4 e, and commitment to long-term treatment and medication compliance.
5 nhaler technique [0.53 (0.475; 0.585)], poor medication compliance [0.385 (-0.007; 0.777)], and gende
6 fter transplantation is associated with poor medication compliance and this may increase risk of graf
7  treatment discontinuations, adverse events, medication compliance, and change in mood.
8 s strategies to enhance treatment retention, medication compliance, and outcome for naltrexone treatm
9                     The primary obstacles to medication compliance appear to be situational/environme
10 self-management plan use, inhaler technique, medication compliance) appear to be the predominant infl
11 complete the trial for personal reasons, and medication compliance averaged 90% in the remaining subj
12                Intensive efforts to increase medication compliance before month 8 posttransplantation
13 ns impact patient safety when monitoring for medication compliance, drug substitution, or misuse/abus
14                             As an adjunct to medication compliance enhancement treatment, topiramate
15 arkers to assess appropriate drug dosage and medication compliance in patients undergoing primary che
16   These further underscore the importance of medication compliance in prevention of ABMR and possibly
17 s than placebo as an adjunct to standardised medication compliance management in treatment of alcohol
18 , and 75 had placebo and weekly standardized medication compliance management.
19 placebo as an adjunct to weekly standardised medication compliance management.
20 ve persistently poor control despite optimal medication compliance, newly emerging pharmaceuticals, i
21                                          The medication compliance of 77 homeless persons who had bee
22  no significant between-group differences in medication compliance or HRQOL.
23 R, 0.37; 95% CI, 0.15-0.90) and prescription medication compliance (OR, 0.35; 95% CI, 0.14-0.85).
24 ternative to "universal" DOT in managing the medication compliance problem when treating TB.
25                                              Medication compliance rates among a cohort of homeless p
26                         This study describes medication compliance rates among a group of homeless me
27 study completion, therapy participation, and medication compliance rates in the trial were high, with
28 imulate the effect of environmental factors, medication compliance, seasonality, and medical history
29                                              Medication compliance, the focus of most compliance-rela
30 epartment [ED] visits, hospitalizations, and medication compliance), training, customized patient edu
31                                              Medication compliance was associated with fewer psychiat
32                                              Medication compliance was measured by two items: 1) Freq
33                                              Medication compliance was monitored using a riboflavin m
34                                              Medication compliance was verified by observed capsule a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。